Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Qiagen is making two agreements to add new biomarkers involving glioblastoma, lymphoma, and other cancers to its portfolio of potential companion diagnostics. The first agreement, a glioblastoma project, is an exclusive worldwide licensing option with Columbia University on FGFR-TACC fusion genes. Qiagen says it intends to develop this biomarker into a diagnostic test for routine use in diagnostic workups, which may enable doctors to identify glioblastoma patients who could benefit from targeted treatments now under development. The second agreement is another exclusive license option, this one with the BC Cancer Agency for a EZH2 Y641 mutation biomarker that could reportedly serve as a companion diagnostic test for routine selection of patients who could benefit from EZH2-targeted therapies that are currently under development by large pharmaceutical companies.
Help employers find you! Check out all the jobs and post your resume.
